- Home
- SLDB
as 12-18-2024 1:42pm EST
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | CHARLESTOWN |
| Market Cap: | 227.3M | IPO Year: | 2018 |
| Target Price: | $17.91 | AVG Volume (30 days): | 295.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.37 - $15.05 | Next Earning Date: | 11-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Solid Biosciences Inc. (SLDB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Herzich Paul | SLDB | Chief Technology Officer | Dec 2 '24 | Sell | $5.60 | 2,777 | $15,550.64 | 12,182 | |
| Cumbo Alexander | SLDB | President and CEO | Dec 2 '24 | Sell | $5.60 | 11,114 | $62,236.18 | 38,484 | |
| Brooks Gabriel | SLDB | Chief Medical Officer | Oct 18 '24 | Sell | $6.50 | 2,923 | $18,999.50 | 10,979 |
Latest Solid Biosciences Inc. News
SLDB Breaking Stock News: Dive into SLDB Ticker-Specific Updates for Smart Investing
Benzinga
5 days ago
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst
MT Newswires
5 days ago
Wedbush Initiates Solid Biosciences at Outperform
MT Newswires
5 days ago
Wedbush Initiates Solid Biosciences at Outperform With $16 Price Target
MT Newswires
14 days ago
Solid Biosciences Collaborating With Mayo Clinic to Develop Cardiac Gene Therapies
TipRanks
14 days ago
Solid Biosciences reports inducement grant under Nasdaq listing rule
GlobeNewswire
14 days ago
Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies
GlobeNewswire
15 days ago
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
22 days ago
Solid Biosciences to Participate at Upcoming Investor Conferences
Compare SLDB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLDB Solid Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.